Skip to Content

Generic Rescriptor Availability

Rescriptor is a brand name of delavirdine, approved by the FDA in the following formulation(s):

RESCRIPTOR (delavirdine mesylate - tablet;oral)

  • Manufacturer: VIIV HLTHCARE
    Approval date: April 4, 1997
    Strength(s): 100MG
  • Manufacturer: VIIV HLTHCARE
    Approval date: July 14, 1999
    Strength(s): 200MG [RLD]

Has a generic version of Rescriptor been approved?

No. There is currently no therapeutically equivalent version of Rescriptor available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Rescriptor. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Delavirdine high strength tablet formulation
    Patent 6,177,101
    Issued: January 23, 2001
    Inventor(s): Martino; Alice C. & Bates; Ashley H. & Morozowich; Walter & Lee; E. John
    Assignee(s): Pharmacia & Upjohn Company
    Disclosed is a non-sustained release pharmaceutical tablet composition which comprises a rapidly precipitating drug in an amount from about 5 to about 60% and at least one member selected from the group consisting of a binder in an amount of from about 2 to about 25% and a superdisintegrant in an amount from about 6 to about 40% where the rapidly precipitating drug, "binder" and superdisintegrant are mixed and compressed into a tablet without heating, solvent or grinding.
    Patent expiration dates:
    • June 7, 2019


Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.